Clinical Trials | September 29, 2021
Morpen Labs carves out diagnostics business to unlock value
The new devices company will scale up its teams to create a world-class R&D centre for medical devices in India
The new devices company will scale up its teams to create a world-class R&D centre for medical devices in India
One of the key factors driving the market growth is the rise in the occurrence of chronic cardiovascular diseases such as heart failure and coronary artery disease: Valuates Reports
This test can be run on commonly available qPCR cyclers, thereby, bypassing the need to perform expensive and time-consuming Next-Generation Sequencing
HTL will build, validate and operate a botulinum manufacturing facility in the US
Acne affects up to 50 million Americans annually. The last FDA approval of an acne drug with a new MOA occurred nearly 40 years ago
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
The transaction is expected to close in the Q4FY22
It is part of the company’s pain/analgesics portfolio of OTC products
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Winlevi has been approved by the United States FDA as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older
Subscribe To Our Newsletter & Stay Updated
